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We performed a longitudinal analysis of 661 methicillin-
resistant Staphylococcus aureus (MRSA) isolates obtained 
from patients in a long-term care facility. USA300 clone in-
creased from 11.3% of all MRSA isolates in 2002 to 64.0% 
in 2006 (p<0.0001) and was mostly recovered from skin or 
skin structures (64.3% vs. 27.0% for non-USA300 MRSA; 
p<0.0001).
S
ince 2001, a dramatic increase in methicillin-resistant 
Staphylococcus  aureus  (MRSA)  infections  has  been 
observed in the United States, mostly related to emergence 
of  the  USA300  clone  in  the  community  (1)  and  subse-
quently in hospitals (2,3). Residents of long-term care fa-
cilities (LTCFs) are at risk for colonization with antimicro-
bial drug–resistant bacteria, including MRSA. After they 
have been colonized, these residents are at increased risk 
for infections (4). Although it is assumed that transfer of 
patients between acute-care hospitals and LTCFs provides 
an ongoing cycle for the introduction of MRSA between 
these facilities (5), few studies have described the molecu-
lar epidemiology of MRSA in LTCFs. We report the preva-
lence and distribution of MRSA genotypes among clinical 
isolates obtained over a 10-year period (1997–2006) at the 
main LTCF in San Francisco, California, USA.
The Study
The San Francisco Laguna Honda Hospital is a 1,000-
bed LTCF. We conducted a retrospective review of elec-
tronic records for all cultures positive for S. aureus that 
originated  from  hospital  residents  during  1997–2006. 
Colonization screening was not performed during the study 
period. Data collection was approved by the Committee on 
Human Research, Office of Research Administration, at the 
University of California, San Francisco.
Isolates  were  tested  for  oxacillin  resistance  by  the 
salt agar method, and the presence of the mecA gene was 
confirmed by PCR. Susceptibility to other antimicrobial 
drugs was determined by using microbroth dilution with 
the MicroScan WalkAway 96 instrument (Dade Behring, 
Deerfield, IL, USA). Inducible clindamycin-resistance test-
ing (D-zone test) was performed by using the agar disk-
diffusion method for isolates obtained during 2005–2006. 
Results  were  interpreted  in  accordance  with  guidelines 
(M7-A5) of the Clinical and Laboratory Standards Institute 
(Wayne, PA, USA; www.clsi.org).
Nonduplicated  MRSA  isolates  were  genotyped  by 
pulsed-field gel electrophoresis (PFGE) after digestion of 
chromosomal DNA with SmaI (6), spa typing (7), and mul-
tilocus sequence typing (MLST) (8). USA300 was defined 
by  the  presence  of  Panton-Valentine  leukocidin  (PVL) 
genes (lukF-PV and lukS-PV) and the arginine catabolic 
mobile element (ACME), detected by PCR. Staphylococcal 
cassette chromosome mec (SCCmec) type was identified by 
using a PCR-based protocol (9). All strains underwent spa 
typing and were tested for PVL and ACME genes. MLST 
was conducted for 12 strains that could not be characterized 
otherwise.
Chi-square tests were used for bivariate analysis, and 
χ2 tests for trend were used to evaluate secular trends. All 
statistical analysis was conducted by using Stata version 
9.1 (Stata Corp., College Station, TX, USA).
S. aureus was isolated from 1,284 patients. Of these iso-
lates, 744 (57.9%) were MRSA. The proportion of MRSA 
among S. aureus isolates increased from 38.1% (56/147) in 
1997 to 72.3% (99/137) in 2006 (p<0.0001; Figure 1). Me-
dian age (interquartile range [IQR]) was 67 years (54–78 
years) for patients with MRSA and 64 years (49–78 years) 
for those with methicillin-susceptible S. aureus (MSSA)   
(p = 0.22). Male:female ratio was 1:2.2 for MRSA and 1:1.7 
for MSSA (p = 0.12). For MRSA specimen sources, we 
observed a decrease in the proportion of urinary or respira-
tory specimens from 69.7% (131/188) during 1997–2000 
to 49.5% (236/477) during 2001–2006, and a concomitant 
increase in the proportion of skin or skin structure speci-
mens from 22.3% (42/188) to 42.8% (204/477) (p<0.0001; 
Figure 2). No change in specimen sources was observed 
for MSSA.
Three PFGE clonal groups (USA100 [ST5, SCCmec 
type II], USA300 [ST8, SCCmec type IV], and USA500 
[ST8, SCCmec type IV]) accounted for 85.2% (563/661) 
of genotyped MRSA isolates. USA300 was first isolated in 
2001 and accounted for 11.3% of all MRSA (7/62) in 2002, 
30.1%  (25/83)  in  2003,  47.9%  (45/94)  in  2004,  49.5% 
(49/99) in 2005, and 64.0% (55/86) in 2006 (p<0.0001; 
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California, USAFigure 1). Compared with non-USA300 MRSA, USA300 
was most frequently isolated from skin or skin structures 
(64.3% vs. 27.0%, risk ratio 2.38, 95% confidence interval 
1.98–2.87, p<0.0001) and was recovered from younger pa-
tients with a median age (IQR) of 62 years (51–75 years) 
vs. 68 years (54–79 years; p = 0.001).
Among  all  MRSA  isolates,  gentamicin  resistance 
decreased from 46.9% in 1997 to 4.7% in 2006, and clin-
damycin resistance decreased from 71.4% to 47.6% for the 
same years (p<0.0001). Overall, 285/744 (38.3%) MRSA 
isolates  were  multidrug  resistant  (resistant  to  >3  non- 
β-lactam antimicrobial drugs), including 177/299 (59.2%) 
USA100,  39/182  (21.4%)  USA300,  and  32/82  (39.0%) 
USA500. Inducible clindamycin resistance was detected 
in 15/281 (5.3%) MRSA isolates during 2005–2006. The 
rate of multidrug resistance for USA300 was lower than for 
non-USA300 (p<0.0001) but increased from 0% in 2001 to 
14.3% (1/7) in 2002, 12.0% (3/25) in 2003, 13.3% (6/45) 
in 2004, 24.5% (12/49) in 2005, and 30.9% (17/55) in 2006 
(p = 0.015). USA300 was less frequently resistant than 
non-USA300 to clindamycin (p<0.0001), gentamicin (p = 
0.0004), and trimethoprim/sulfamethoxazole (p = 0.0001) 
and more frequently resistant to tetracycline (p = 0.0002) 
(Table). Resistance to vancomycin, linezolid, dalbavancin, 
and daptomycin was not detected.
Conclusions
Increasing  incidence  of  MRSA  infections  in  this 
LTCF during 1997–2006 is attributable to 2 clonal groups; 
USA100 predominated until 2003, and USA300 predomi-
nated during 2004 2006. Emergence of a new MRSA clone 
in healthcare facilities may be followed by a decrease in in-
cidence of other MRSA clones (10). Unfortunately, this de-
crease was not observed in this LTCF, where the incidence 
of  the  previously  predominant  clone  USA100  remained 
unabated. As a consequence, emergence of USA300 led to 
a 2-fold increase in MRSA incidence and an increase to 
73% in the rate of methicillin resistance among S. aureus. 
Moreover, because USA300 has a tropism for skin and 
skin structure infections (3), its emergence caused a shift in 
MRSA specimen sources.
Although primarily encountered in urinary and respi-
ratory specimens until 2001 in this study, as in previous 
studies performed in LTCFs, MRSA isolates have mostly 
originated from skin or skin structure since 2002. This find-
ing has important implications for MRSA transmission and 
should be taken into account when designing infection con-
trol policies in LTCFs. For example, nasal decolonization 
as a means to prevent MRSA infection implies that MRSA 
reservoirs reside in endogenous sources. However, skin–
skin and skin–fomite contact may represent common alter-
native routes of transmission for USA300 (11).
In contrast to reports characterizing USA300 strains 
as typically not multidrug resistant (1), we found that up to 
30.9% of USA300 isolates were multidrug resistant. This 
finding suggests that USA300 isolates were acquired un-
der antimicrobial drug pressure in the LTCF or during a 
stay in another hospital rather than while in contact with 
the community. Results from this study and others illus-
trate the fitness trait of USA300 clonal lineage (12). To 
prevent further spread of multidrug-resistant USA300 in 
LTCFs would require enhanced infection control policies, 
which may include isolation or cohorting of infected pa-
tients, antimicrobial drug stewardship, and systematic use 
of alcohol-based handwashing products. However, given 
that these policies have proven difficult to implement in 
tertiary care hospitals, it may be even more challenging in 
LTCFs, which have limited staff and infection control re-
sources (5,13–15).
This study had some limitations. Increased incidence 
of MRSA-positive cultures could be related to changes in 
sampling policies in this institution (e.g., more frequent 
sampling, surveillance cultures). However, the increased 
incidence  rate  for  MRSA  is  not  likely  related  to  these 
changes because the annual number of cultures positive for 
any pathogen gradually decreased over the study period, 
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Figure  1.  Longitudinal  dynamics  of  methicillin  resistance  and 
methicillin-resistant  Staphylococcus  aureus  (MRSA)  clones  at  a 
long-term care facility, San Francisco, California, USA, 1997–2006.
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Figure 2. Evolution of methicillin-resistant Staphylococcus aureus 
isolate specimen sources at a long-term care facility, San Francisco, 
California, USA, 1997–2006.MRSA USA300 Clone in Long-Term Care Facility
from 1,433 in 1997 to 862 in 2006, as did the incidence of 
MSSA-positive cultures, from 91 in 1997 to 38 in 2006.
Although our study was limited by its reliance on ret-
rospective data collection, it illustrates the need for further 
investigations in LTCFs regarding risk factors and appro-
priate  interventions  to  minimize  further  transmission  of 
MRSA. LTCFs, long thought to be reservoirs of nosoco-
mial MRSA clones, now emerge as an important reservoir 
for USA300 and could play a role in the emergence of 
multidrug-resistant USA300.
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Table. Analysis of MRSA clones obtained in a long-term care facility, San Francisco, California, USA, 1997–2006*  
Antimicrobial drug resistance, %  Specimen source, % 
Clonal group  Ery  Cli Cip Sxt Gen Tet SST Respiratory tract  Urine Blood†
USA100 (n = 299)  96.2 84.9 95.9 3.3 16.9 2.6 22.7 36.4 35.1 5.8
USA300 (n = 182)  87.8 15.0 79.4 0.6 6.1 13.2 64.3 18.1 10.4 7.1
USA500 (n = 82)  84.7 27.8 71.7 28.2 20.8 6.0 30.5 28 31.7 9.8
LFT (n = 98) 87.3 65.6 62.8 10.9 13.4 7.8 37.2 26.6 26.6 9.6
All MRSA (n = 744)  91.8 64.6 87.0 7.1 21.6 5.1 32.7 25.1 23.1 6.3
*MRSA, methicillin-resistant Staphylococcus aureus; Ery, erythromycin; Cli, clindamycin; Cip, ciprofloxacin; Sxt, trimethoprim-sulfamethozazole; Gen, 
gentamicin; Tet, tetracycline; SST, skin and skin structure; LFT, low frequency types. 
†Blood and other typically sterile sites. 